Sevitan-HTZ is indicated for the treatment of hypertension
The usual starting dose of Sevitan-HTZ is 20/12.5 mg one tablet once daily. Dosing should be individualized. Depending on the blood pressure response, the dose may be titrated at intervals of 2-4 weeks.
Patients with Renal Impairment-
The usual regimens of therapy with Sevitan-HTZ may be followed provided the patients creatinine clearance is >30 ml/min. In patients with more severe renal impairment, loop diuretics are preferred to thiazides. So, Sevitan-HTZ is not recommended.
Patients with Hepatic Impairment-
No dosage adjustment is necessary with hepatic impairment.
The combination of Olmesartan and Hydrochlorothiazide is contraindicated in patients who are hypersensitive to any component of this product. Because of the Hydrochlorothiazide component, this product is contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs.
The common side-effects are nausea, headache, dizziness, hyperuricemia, upper respiratory tract infection and urinary tract infection. Other adverse effects are chest pain, back pain, peripheral edema, abdominal pain, dyspepsia, gastroenteritis, and diarrhea.
The drug should be discontinued during these conditions.
â€¢ Periodic determination of serum electrolytes should be performed at appropriate intervals to detect possible electrolyte imbalance like hypokalemia, hyponatremia and hypochloremic alkalosis
â€¢ Hyperuricemia may occur in certain patients receiving thiazide therapy
â€¢ Impaired renal function
Store in a cool and dry place, protect from light and moisture.
Keep out of the reach of children.